Momenta Phama (MNTA) Launches Phase 2/3 Trial of M281; Granted FDA Fast Track

Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA) announced the launch of an adaptive Phase 2/3 clinical study for its FcRn inhibitor nipocalimab. FDA Fast Track granted for Nipocalimab in wAIHA.

https://www.streetinsider.com/Corporate+News/Momenta+Phama+%28MNTA%29+Launches+Phase+23+Trial+of+M281%3B+Granted+FDA+Fast+Track+for+Nipocalimab+in+wAIHA/15768861.html